OnabotulinumtoxinA | B103000 | ALLERGAN
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 7-Year Orphan | Jun. 20, 2026 | Expired | Purple Book |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12241098(manufacturing) · relevance 92/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 192 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Allergan, Inc. v. Revance Therapeutics, Inc. et al 5 patentsbotulinum neurotoxin type A (BoNT/A), OnabotulinumtoxinA | D. Del. | 2021-10-01 | Active | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.